|
| Primary information |
|---|
| ID | 11722 |
| Therapeutic ID | Th1254 |
| Protein Name | Capromab pendetide |
| Sequence | NA
|
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | 61 °C (FAB fragment), 71 °C (whole mAb) |
| Half-life | NA |
| Description | Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide [Indium In-111] during imaging to evaluate the extent of prostate cancer. |
| Indication/Disease | For diagnosis of prostate cancer and detection of intra-pelvic metastases. |
| Pharmacodynamics | Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors. |
| Mechanism of Action | Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors. |
| Toxicity | NA |
| Metabolism | Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production |
| Absorption | NA |
| * 4 ± 2.1 L |
| Clearance | * 42 +/- 22 mL/hr |
| Categories | Diagnostic Radiopharmaceuticals |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Glutamate carboxypeptidase 2 |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |